Publication

Article

Oncology Nursing News

April 2011
Volume5
Issue 2

The Meaning of Breast Cancer Risk and Surveillance Behaviors Among High-Risk African-American Women

Author(s):

A breast cancer diagnosis is a highly distressing, life-changing experience

Marlene Z. Cohen, PhD, RN, FAAN

Marlene Z. Cohen, PhD, RN, FAAN

A breast cancer diagnosis is a highly distressing, life-changing experience. A small study presented at the Oncology Nursing Society 11th National Conference on Cancer Nursing showed that just being at a higher risk for the disease can also alter a woman’s life.

“It was surprising to me how very distressing the risk status itself is to both the women and their loved ones,” said Marlene Z. Cohen, PhD, RN, FAAN, from the University of Nebraska Medical Center, Omaha, in a press release. Cohen presented the research along with Janice Phillips, PhD, RN, FAAN, from the Nursing Research and Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Illinois.

Janice Phillips, PhD, RN, FAAN

Janice Phillips, PhD, RN, FAAN

The researchers interviewed 19 African-American women aged 22 to 40 years who were considered to be at a high risk for breast cancer. High risk was defi ned as having a personal or family history of breast cancer and/or carrying a gene mutation linked to breast cancer. Overall, in women aged <45 years, African-American women’s risk for breast cancer is higher than Caucasian women’s risk. Young African-American women also frequently present at late stage with few treatment options.

A majority of study participants reported that the high-risk status had changed their life. They described how being at a higher cancer risk altered their relationships and interactions with their family and friends. “It was clear that education and support is needed for these women and their families, as well as for nurses who care for and counsel high-risk populations,” Phillips said in a press release.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center